Modular Medical finalizes GLP-1 personalized metabolic therapy study protocol

Modular Medical announced an update on its proof-of-concept study in a high-fat diet-induced obese mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. The Company has finalized its protocol for the proof-of concept study, which is now expected to commence in October 2024 with data readout in November 2024. “We see the MODD1 as a transformative platform with many different applications outside of diabetes care, and, with our US Food and Drug Administration clearance in hand, we now have the credibility in the market to explore other use cases without distracting from our primary focus of improving care for the “almost pumpers,” stated Jeb Besser, CEO of Modular Medical. “Our first effort in this regard will be the data readout in November of our proof-of-concept study using a rapid acting GLP1 to treat those who are unable to tolerate once weekly shots. This program would require no material changes to our basic MODD1 design, and, if we can demonstrate good glycemic control and weight loss efficacy with fewer GI side effects than the once weekly shots, we believe the market for those who cannot tolerate the one size fits all weekly therapies is potentially as large as our base insulin pump business. If successful, this is a project we would ultimately seek to partner with a drug manufacturer that would take lead on clearance and marketing.”